ASKA Pharmaceutical Holdings Co Ltd 2025 Integrated Report
Company: ASKA Pharmaceutical Holdings Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2025
Type: Integrated Report
Pages: 100
The report describes ASKA Pharmaceutical Holdings' FY2024 performance as the Group expanded its healthcare portfolio and consolidated Hataphar in Vietnam. It quantifies an estimated ¥81.3 billion reduction in economic loss from women's menstrual symptoms through medicines and awareness initiatives. Environmental highlights include a 53.6% reduction in CO2 emissions from FY2013 and first-time Scope 3 reporting. The report also details TCFD and TNFD-related disclosures, human-capital initiatives, and progress in diversity and women's advancement.
Reporting standards, commitments and assurance details are available with a free account.
Data Services
From bulk PDFs to structured indicators and machine-readable documents.